1 / 14

Supersensitive magnetocardiographic system for early recognition, precise diagnostics and monitoring of heart diseases

Supersensitive magnetocardiographic system for early recognition, precise diagnostics and monitoring of heart diseases. 12.10.2006 Kiev Dr.Volodymyr Sosnytskyy +38(044)5013072 sosna@uninet.kiev.ua Kiev Medical Group, Ltd. Kiev. Proprietary information statement.

garnet
Download Presentation

Supersensitive magnetocardiographic system for early recognition, precise diagnostics and monitoring of heart diseases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supersensitive magnetocardiographic system for early recognition, precise diagnostics and monitoring of heart diseases 12.10.2006 Kiev Dr.Volodymyr Sosnytskyy +38(044)5013072 sosna@uninet.kiev.ua Kiev Medical Group, Ltd. Kiev

  2. Proprietary information statement • The technology material presented in this talk is available for licensing or joint product development. • None of the slides contain any confidential or proprietary information which would prevent patenting the technology.

  3. Problem Description & Market Need - Ischemic heart disease is the leading cause of death in Western countries. • The early noninvasive diagnosis of ischemia is one of the major clinical problems that could benefit from the additional information provided by MCG. • MCG can identify propensity to ventricular arrhythmias, in heart diseases , independently of other clinical variables. • Contactless MCG can be ideal for research and development of new drugs and for experimental evaluation of gene therapy. • The vicious circle: lack of clinical equipment -> clinician skepticism ( lack of experience) -> lack of evidence-based clinical benefit -> no real market -> lack of investment -> lack of development of clinical equipment.

  4. Brief technology description • MCG is the measurement of magnetic fields emitted by the human heart from small currents by electrically active cells of the heart muscle. • MCG is a completely noninvasive method that permits the registration of cardiac electrical activity at multiple site in a plane above the chest cage without the need for electrodes. • MCG is both a method to record cardiac signals and to provide 3D functional imaging of cardiac electrophysiology.

  5. Averaged MCG 36-channels Normal MCG Map of magnetic field distribution on Tapex Map of current density distribution on Tapex

  6. Advantages • MCG is modern imaging and quantitative analysis technique for detection abnormal difference in electrophysiological cardiac phenomena • Magnetocardiography (MCG) is a noninvasive and risk-free technique for contactless surface mapping of the magnetic fields generated by the electrical activity of the heart. • This SQUID-based MCG system has a high potential for health care, especially because it could be used in hospital environments without expensive and inflexible magnetic shielded rooms. • Recent availability of budget-price multichannel minisystems for unshielded MCG. • MCG has been accepted as a clinical tool.

  7. Experimental results MCG – Animal Studies PHANTOM AND SOURCE MODELING

  8. Clinical Trials (CAD with normal ECG vs. Controls) Sensitivity & Specificity of MCG in CAD with normal ECG PET - 90 - - 80 - - 70 - - 60 - - 50 - - 40 - - 30 - - 20 - - 10 - PET MCG 84.6 % MCG 90.5 % Stress Scintigraphy Stress-EchoCG Stress-EchoCG Stress Scintigraphy Exercise-ECG Sensitivity Specificity Exercise-ECG Holter monitoring Holter monitoring ECG at rest ECG at rest

  9. Stage of development • System is ready for application • Clinical Trials: detection of myocardial ischemia and arrhythmogenic risk assessment

  10. Targeted Market Segment • MCG can be used for noninvasive diagnosis of cardiac events related to : - coronary artery disease (CAD), - safety of all medical drugs with respect to the drugs potential to cause heart arrhythmia, - early detection of graft rejection after cardiac transplantation, - pathophysiological role and therapeutic potential of stem cells . Introduction of MCG diagnostics into routine clinical practice can improve patient outcomes, decrease mortality and risks, increase comfort and significantly reduce cost of health care. The cost of commercially available few-channel systems for unshielded MCG range between 200,000 and 500,000 US$

  11. Competition • More expensive or invasive methods: - Stress-echocardiography, - Single photon emission computed tomography (SPECT) - Coronary angiography The cost of the equipment for MCG differs widely as function of approach prefered. Small unshielded systems can now be operated by nurses or research technicians

  12. Competitive Matrix

  13. Opportunities We look forward on international collaboration for : • clinical trials • joint product development

  14. Contact information Dr.Volodymyr Sosnytskyy +38(044)5013072 sosna@uninet.kiev.ua Kiev Medical Group, Ltd. Kiev

More Related